Skin and hair
87 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Abrocitinib for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ABS-201 SC Multiple Doses + Placebo SC Injection for alopecia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AD-303A for alopecia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Adalimumab for alopecia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AdMSC for scleroderma, systemic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amlitelimab for eczema | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Anti Thymocyte Globulin + GM-CSF + Total Body Irradiation + ALEMTUZUMAB + RITUXIMAB + HUMAN IMMUNOGLOBULIN G + Cyclophosphamide + THIOTEPA + Mesna for scleroderma, diffuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| anti-CD19 CAR-T cells for scleroderma, systemic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATI-045 for eczema | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATTO-1310 for pruritus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AZD0120 for scleroderma, systemic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Baricitinib for alopecia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Baricitinib for alopecia areata | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Belimumab for scleroderma, diffuse | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Beremagene geperpavec for epidermolysis bullosa dystrophica | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bimekizumab for psoriasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood Specimen Collection + Photographs of Rash + Questionnaires + Stool Specimen collection + Doxycycline for acneiform eruptions | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood Specimen Collection + Photographs of Rash + Questionnaires + Stool Specimen collection + Isotretinoin for acneiform eruptions | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Botulinum toxin type a for alopecia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CAR-T cells targeting CD19 for scleroderma, systemic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clinical decision support tool for keratosis, seborrheic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Crisaborole 2% topical ointment for vitiligo | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyclophosphamide + FLUDARABINE + Prulacabtagene Leucel for scleroderma, systemic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DB-2304 + Placebo for lupus erythematosus, cutaneous | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DB-2304 + Placebo + Prednisone for lupus erythematosus, cutaneous | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deucravacitinib for psoriasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deucravacitinib for vitiligo | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deuruxolitinib for alopecia areata | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diacerein for epidermolysis bullosa simplex | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dupilumab for dermatitis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dupilumab for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Famotidine and 4% topical cromolyn sodium for pruritus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Gentamicin for ichthyosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-intensity Mediterranean diet intervention for psoriasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for alopecia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes (hUC-MSC-Exos) Intravenous Infusion for vitiligo | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes (hUC-MSC-Exos) Local Injection for vitiligo | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lactiplantibacillus plantarum for psoriasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lebrikizumab for dermatitis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lebrikizumab for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lenalidomide for lupus erythematosus, cutaneous | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mesenchymal Stem Cells for alopecia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metformin for melanosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Minoxidil for alopecia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| MTX-474 for scleroderma, diffuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Music Therapy for psoriasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Neolizumab for epidermolysis bullosa dystrophica | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Neolizumab for pruritus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Neovasculgen® for foot ulcer | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Optical Coherence Tomography + Reflectance confocal microscopy + DUPILUMAB for eczema | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for alopecia areata | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Placebo for pruritus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo - 100 mg + Ritlecitinib 50 mg for alopecia areata | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo - 50 mg + Ritlecitinib 100 mg for alopecia areata | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + DUPILUMAB for eczema | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + LEBRIKIZUMAB for eczema | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Upadacitinib for alopecia areata | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo IV + SAD IV Dose 1 - 150mg ABS201 IV Single Dose for alopecia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PP405 0.05% Topical Gel for alopecia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PTX-022 for pachyonychia congenita | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| QEL-005 for scleroderma, diffuse | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Risankizumab for psoriasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ritlecitinib 100 mg for alopecia areata | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rituximab + belimumab for scleroderma, systemic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Roflumilast for dermatitis, seborrheic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Roflumilast for psoriasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ruxolitinib for lichen sclerosus et atrophicus | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ruxolitinib for vitiligo | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Saccharomyces cerevisiae for ichthyosis bullosa of siemens | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Scar gel for keloid | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Small interfering RNA (siRNA) Microneedle Patches for keloid | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SPY002-072 for collagen diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Suzetrigine for breast diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Suzetrigine for nail diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tapinarof for keratoderma, palmoplantar | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TAR-0520 gel for hand-foot syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Telitacicept for scleroderma, diffuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Topical emollient (moisturizer) + DUPILUMAB for pruritus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tranexamic acid for hyperpigmentation | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tulisokibart for scleroderma, diffuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Upadacitinib for alopecia areata | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Ustekinumab for alopecia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VDPHL01 for alopecia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| VDPHL01 BID for alopecia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VDPHL01 QD for alopecia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zasocitinib for psoriasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |